Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro

Mihatsch, Julia; Toulany, Mahmoud; Bareiss, Petra M.; Grimm, Sabrina; Lengerke, Claudia; Kehlbach, Rainer; Rodemann, H. Peter

doi:10.1016/j.radonc.2011.06.003

Cited by 68 publications

(57 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, the role of CD133 expression as a prognostic marker in NSCLC has been debated (46)(47)(48)(49)(50)(51). CD133 has been found to be significantly correlated with pathological stages II-IV in NSCLC and was an independent poor factor for prognosis (49) however, Salnikov et al (51) reported CD133 may be used as a predictor for efficacy of cytotoxic therapy, but it does not represent a prognostic marker for positive in NSCLC.…”

Section: Cd133mentioning

confidence: 99%

Lung cancer stem cells—characteristics, phenotype

Hardavella¹,

George²,

Sethi³

2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

Lung cancer remains a major cause of cancer-related deaths worldwide with unfavourable prognosis mainly due to the late stage of disease at presentation. High incidence and disease recurrence rates are a fact despite advances in treatment. Ongoing experimental and clinical observations suggest that the malignant phenotype in lung cancer is sustained by lung cancer stem cells (CSCs) which are putative stem cells situated throughout the airways that have the potential of initiating lung cancer formation. These cells share the common characteristic of increased proliferation and differentiation, long life span and resistance to chemotherapy and radiation therapy. This review summarises the current knowledge on their characteristics and phenotype.

show abstract

Section: Cd133mentioning

confidence: 99%

Lung cancer stem cells—characteristics, phenotype

Hardavella¹,

George²,

Sethi³

2016

Transl. Lung Cancer Res.

View full text Add to dashboard Cite

show abstract

“…With respect to the described functional role of the PI3K/Akt pathway in CSCs [129,143] and the role of cancer stem cells in radiotherapy outcomes [135], inhibition of the Akt pathway might offer an improved response to radiation in CSCs [137,141,144]. Based on the assumption that CSCs are more radioresistant and that they present Akt pathway hyperactivation, our laboratory has shown that a selected radioresistant subpopulations of NSCLC-A549 cells that present the CSC marker ALDH1 can be radiosensitized by the PI3K inhibitor LY294002 [145]. The importance of PI3K/Akt signaling to radioresistance in CSCs is also underlined by data indicating the Akt-dependence of accelerated repair of radiation-induced DNA-DSB [141], especially in brain tumor stem cell [146].…”

Section: Importance Of Akt In Radiotherapy Resistancementioning

confidence: 99%

Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation

Toulany

Rodemann

2015

Seminars in Cancer Biology

Self Cite

136

View full text Add to dashboard Cite

“…Since ALDH1-positive CSCs are thought to be resistant to chemotherapy [7] and radiation therapy [24], it was speculated that recurrence after breast-conserving treatment might be higher for ALDH1-positive than for ALDH1-negative DCIS. However, we found that, although admittedly the number of patients in either group was small, the recurrence rates were very low and similar for both tumors.…”

Section: Discussionmentioning

confidence: 99%

Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells

et al. 2013

View full text Add to dashboard Cite

Objective: The aim of this study was to elucidate the clinicopathological characteristics of breast ductal carcinomas in situ (DCIS) with aldehyde dehydrogenase 1 (ALDH1)-positive cancer stem cells (CSCs). Methods: DCIS (n = 194) were subjected to immunohistochemical staining and results were examined for associations with various clinicopathological parameters. The ALDEFLUOR assay for breast cancer cell lines was also performed to determine the proportion of CSCs according to intrinsic subtype. Results: DCIS with ALDH1-positive CSCs were significantly (p < 0.05) more likely to be estrogen receptor-α (ER)-negative, progesterone receptor (PgR)-negative, Ki67-positive and HER2-positive tumors. Luminal A subtype (8.6%) showed a significantly (p < 0.001) lower ALDH1 positivity than the other subtypes [luminal B (50.0%), luminal HER2 (36.8%), HER2 (35.3%) and triple-negative subtype (26.7%)]. Double immunostaining revealed that ALDH1-positive CSCs did not overlap with ER-, PgR- or Ki67-positive tumor cells but did overlap with HER2-positive tumor cells. The percentage of ALDEFLUOR-positive CSCs was lower in the luminal A cell lines (0.02% for T-47D and 0.4% for MCF7) than in the luminal HER2 (9.1% for BT-474 and 9.5% for MDA-MB-361), HER2 (13.9% for AU565 and 33.2% for SK-BR-3) and triple-negative cell lines (28.4% for MDA-MB-231 and 30.7% for MDA-MB-468). Conclusions: Our results suggest that most CSCs in DCIS are in the G0 phase (Ki67 negative) and do not express ER or PgR, but they do express HER2 in HER2-positive tumors.

show abstract

Selection of radioresistant tumor cells and presence of ALDH1 activity in vitro

Cited by 68 publications

References 47 publications

Lung cancer stem cells—characteristics, phenotype

Lung cancer stem cells—characteristics, phenotype

Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation

Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells

Contact Info

Product

Resources

About